Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy

Clinical Infectious Diseases

Volumn 39, Issue 11, 2004, Pages 1681-1691

  Antinori, Andrea ^a,l   Larussa, Dora ^a   Cingolani, Antonella ^a   Lorenzini, Patrizia ^a   Bossolasco, Simona ^c   Finazzi, Maria Grazia ^b   Bongiovanni, Marco ^d   Guaraldi, Giovanni ^f   Grisetti, Susanna ^a   Vigo, Beniamino ^e   Gigli, Beniamino ^a   Mariano, Andrea ^g   Dalle Nogare, Ernesto Renato ^h   De Marco, Michele ^a   Moretti, Francesca ⁱ   Corsi, Paola ^j   Abrescia, Nicola ^k   Rellecati, Patrizia ^a   Castagna, Antonella ^c   Mussini, Cristina ^f   Ammassari, Adriana ^a   Cinque, Paola ^c   D'Arminio Monforte, Antonella ^d   more..

^a CATHOLIC UNIVERSITY   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e OSPEDALE NIGUARDA CA GRANDA   (Italy)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^g UNIVERSITY OF PERUGIA   (Italy)

^h Divisione Malattie Infettive   (Italy)

ⁱ UNIVERSITY OF BRESCIA   (Italy)

^j CAREGGI UNIVERSITY HOSPITAL   (Italy)

^k AO Dei Colli Hospital for Infectious Diseases D Cotugno   (Italy)

^l NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPROTOZOAL AGENT; ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BRAIN ATROPHY; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ENCEPHALITIS; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; SURVIVAL RATE; TOXOPLASMA; TOXOPLASMOSIS; TREATMENT FAILURE; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ENCEPHALITIS; FEMALE; HUMANS; MALE; PREVALENCE; PROGNOSIS; SURVIVAL RATE; TOXOPLASMOSIS, CEREBRAL;

EID: 9644266860     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/424877     Document Type: Article

References (47)

1. Luft B, Remington J. Toxoplasmic encephalitis in AIDS. Clin Infect Dis 1992; 15:211-22.
2. Bacellar H, Munoz A, Miller EN, et al. Temporal trends in the incidence of HIV-related neurologic diseases: Multicenter AIDS Cohort Study, 1985-1992. Neurology 1994; 44:1892-900.
3. Belanger F, Derouin F, Grangeot-Keros L, Meyer L. Incidence and risk factors of toxoplasmosis in a cohort of human immunodeficiency virus infected patients: 1988-1995. Clin Infect Dis 1999; 28:575-81.
4. Ammassari A, Scoppettuolo G, Murri R, et al. Changing disease patterns in focal brain lesion-causing disorders in AIDS. J Acquir Immune Defic Syndr 1998; 18:365-71.
5. Sacktor N, Lyles RH, Skolasky R, et al. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990-1998. Neurology 2001; 56:257-60.
6. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
7. Mocroft A, Youle M, Phillips AN, et al. The incidence of AIDS-defining illnesses in 4883 patients with human immunodeficiency virus infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. Arch Intern Med 1998; 158:491-7.
8. Kaplan JE, Henson D, Dworking MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 30:S5-14.
9. Ammassari A, Cingolani A, Pezzotti P, et al. AIDS-related focal brain lesions in the era of highly active antiretroviral therapy. Neurology 2000; 55:1194-200.
10. d'Arminio Monforte A, Duca PG, Vago L, Grassi MP, Moroni M. Decreasing incidence of CNS AIDS-defining events associated with antiretroviral therapy. Neurology 2000; 54:1856-9.
11. D'Arminio Monforte A, Cinque P, Mocroft A, et al. Changing incidence of CNS HIV-related diseases in the EuroSIDA cohort. Ann Neurol 2004; 55:320-8.
12. Abgrall S, Rabaud C, Costagliola D. Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era. Clin Infect Dis 2001; 33:1747-55.
13. Jones JL, Sehgal M, Maguire JH. Toxoplasmosis-associated deaths among human immunodeficiency virus-infected persons in the United States, 1992-1998. Clin Infect Dis 2002; 34:1161.
14. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998; 280:1497-503.
15. Mocroft A, Vella S, Benfield TI, et al. Changing pattern of mortality across Europe in patients infected with HIV-1. Euro SIDA Study Group. Lancet 1998; 352:1725-30.
16. Hogg R, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiations of antiretroviral therapy. JAMA 1998; 279:450-4.
17. Antinori A, Cingolani A, Lorenzini P, et al. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol 2003; 9(Suppl 1):47-53.
18. Centers for Disese Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescent and adults. MMWR Recomm Rep 1992; 41:1-19.
19. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-infected patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353:863-8.
20. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999; 282:2220-6.
21. Michelet C, Arvieux C, Francois C, et al. Opportunistic infections occurring during highly active antiretroviral treatment. AIDS 1998; 12:1815-22.
22. Fournier S, Rabian C, Alberti C, et al. Immune recovery under highly active antiretroviral therapy is associated with restoration of lymphocyte proliferation and interferon-gamma production in the presence of Toxoplasma gondii antigens. J Infect Dis 2001; 183:1586-91.
23. Kaplan JE, Masur H, Holmes KK. Discontinuing prophylaxis against recurrent opportunistic infection in HIV-infected persons: a victory in the era of HAART. Ann Intern Med 2002; 137:285-7.
24. Girard PM, Landmen R, Gaudebout C, et al. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group. N EngI J Med 1993; 328:1514-20.
25. Antinori A, Murri R, Ammassari A, et al. Aerosolized pentamidine, cotrimoxazole, and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. AIDS 1995; 9:1343-50.
26. Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995; 332:693-9.
27. San-Andrés FJ, Rubio R, Castilla J, et al. Incidence of acquired immunodeficiency syndrome-associated opportunistic diseases and the effect of treatment on a cohort of 1115 patients infected with human immunodeficiency virus, 1989-1997. Clin Infect Dis 2003; 36:1177-85.
28. Furrer H, Opravil M, Bernasconi E, Telenti A, Egger M. Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis. Swiss HIV Cohort Study Lancet 2000; 355:2217-8.
29. Mussini C, Pezzotti P, Govoni A, et al. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study. J Infect Dis 2000; 181:1635-42.
30. Kirk O, Reiss P, Uberti-Foppa C, et al. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002; 137:239-50.
31. Zeller V, Truffot C, Agher R, et al. Discontinuation of secondary prophylaxis against disseminated Mycobacterium avium complex infection and toxoplasmic encephalitis. Clin Infect Dis 2002; 34:662-7.
32. Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the US Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 2002; 51:1-52.
33. Moroni M. Sex differences in HIV-1 viral load and progression to AIDS. ICONA Study Group. Italian cohort of HIV-1 positive individuals. Lancet 1999; 353:589-90.
34. Sterling TR, Vlahov D, Astemborsky J, et al. Initial plasma HIV-1 RNA level and progression to AIDS in women and men. N Engl J Med 2001; 344:720-5.
35. d'Arminio Monforte A, Cozzi-Lepri A, Rezza G, et al. Insight into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort antiretroviral naive patients. AIDS 2000; 14:499-507.
36. Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active of antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr 2002; 31:S123-7
37. Egger M, May M, Chene G, et al. Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-29.
38. Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases morbidity and mortality in patients with advanced HIV disease. Ann Intern Med 2001; 135:17-26.
39. Wood E, Hogg R, Yip B, et al. Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy? AIDS 2003; 17:711-20.
40. Mocroft A, Ledergeber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-9.
41. Morris A, Wachter RM, Luce J, Turner J, Huang L. Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS 2003; 17:73-80.
42. Dworkin MS, Wan PCT, Hanson DL, Jones JL. Progressive multifocal leukoencephalopathy: improved survival of human immunodeficiency virus-infected patients in the protease inhibitor era. J Infect Dis 1999; 180:621-25.
43. Skiest DJ. Focal neurological disease in patients with acquired immunodeficiency syndrome. Clin Infect Dis 2002; 34:103-15.
44. Lazzarin A, Esposito R, Reale MT, et al. Epidemiology of Toxoplasma encephalitis and need for primary prophylaxis among AIDS patients in northern Italy. J Acquir Immune Defic Syndr 1990; 3:1114-8.
45. Yazdanpanah Y, Chene G, Losina E, et al. Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical coorts. Int J Epidemiol 2001; 30:864-71.
46. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286:2568-77.
47. Palella FJ, Deloria-Knoll M, Chmiel IS, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med 2003; 138:620-6.